Literature DB >> 19076070

Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage.

Iva V Klevernic1, Simon Morton, Roger J Davis, Philip Cohen.   

Abstract

In Ewing's sarcomas, chromosomal translocations cause the N-terminal domain of the EWS (Ewing's sarcoma protein) to fuse with the DNA-binding domains of the Ets (E26 transformation-specific) family of transcription factors. Here we show that EWS and EWS-Fli1 (Friend leukaemia virus integration 1), the fusion most frequently found in Ewing's sarcomas, become phosphorylated at Thr(79) in response to either mitogens or DNA-damaging agents. The much weaker mitogen-induced phosphorylation of EWS is catalysed by the MAPKs (mitogen-activated protein kinases) ERK1 (extracellular signal-regulated kinase 1) and ERK2, whereas the much stronger phosphorylation of EWS induced by the DNA alkylating agent MMS (methyl methanesulphonate) can be catalysed by JNK (c-Jun N-terminal kinase) and at least one other protein kinase distinct from ERK1/ERK2. In contrast, the phosphorylation of EWS-Fli1 induced by MMS was largely mediated by p38alpha/p38beta MAPKs. MMS induced a much stronger phosphorylation of EWS-Fli1 than EWS in heterodimers comprising both proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19076070     DOI: 10.1042/BJ20082097

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  13 in total

Review 1.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

Review 2.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

3.  Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Authors:  Maria E Gierisch; Franziska Pfistner; Laura A Lopez-Garcia; Lena Harder; Beat W Schäfer; Felix K Niggli
Journal:  J Biol Chem       Date:  2016-11-08       Impact factor: 5.157

Review 4.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

5.  Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in response to DNA damage.

Authors:  Tianzhuo Zhang; Zhe Wang; Minghui Liu; Lu Liu; Xin Yang; Yu Zhang; Juntao Bie; Yutong Li; Mengmeng Ren; Chen Song; Wengong Wang; Hongyu Tan; Jianyuan Luo
Journal:  Oncogene       Date:  2022-06-22       Impact factor: 8.756

6.  Downstream EWS/FLI1 - upstream Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Genome Med       Date:  2010-01-28       Impact factor: 11.117

7.  Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity.

Authors:  Silke Schlottmann; Hayriye V Erkizan; Julie S Barber-Rotenberg; Chad Knights; Amrita Cheema; Aykut Uren; Maria L Avantaggiati; Jeffrey A Toretsky
Journal:  Front Oncol       Date:  2012-09-07       Impact factor: 6.244

8.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

9.  XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Authors:  Kathleen I Pishas; Alaknanda Adwal; Susan J Neuhaus; Mark T Clayer; Gelareh Farshid; Alexander H Staudacher; David F Callen
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

10.  Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin.

Authors:  Seon-Gyeong Lee; Namwoo Kim; Su-Min Kim; In Bae Park; Hyejin Kim; Shinseog Kim; Byung-Gyu Kim; Jung Me Hwang; In-Joon Baek; Anton Gartner; Jun Hong Park; Kyungjae Myung
Journal:  EMBO Rep       Date:  2020-10-01       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.